A Prospective Observational Study on Establishment of New Biomarkers to Compensate for Peritoneal Lavage Cytology in Pancreatic Cancer

A Prospective Observational Study on Establishment of New Biomarkers to Compensate for Peritoneal Lavage Cytology in Pancreatic Cancer - New Biomarkers to Compensate for Peritoneal Lavage Cytology in Pancreatic Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045828

Enrollment

180

Registered

2021-10-22

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients clinically diagnosed with pancreatic ductal adenocarcinoma (2) Patients planned to undergo radical resection (3) Patients with a PS (ECOG) of 0 or 1 (4) Patients expected to survive for more than 3 months from the initial treatment (5) Patients with written informed consent

Exclusion criteria

Exclusion criteria: (1) Patients with serious comorbidities (2) Patients with active multiple cancers (3) Patients with mental disease interfering taking part in the trial (4) Pregnant or breast-feeding women, or women suspected of being pregnant (5) Patients who are judged unsuitable for the study by the principal investigator or sub-investigator

Design outcomes

Primary

Measure	Time frame
Prognostic impact of new biomarkers on disease-free survival	—

Countries

Japan

Contacts

Public ContactMasaya Suenaga

National Hospital Organization Nagoya Medical Center Department of Surgery

suenaga.masaya.tk@mail.hosp.go.jp052-951-1111

Outcome results